ANAB

ANAB

USD

AnaptysBio Inc. Common Stock

$34.740-1.230 (-3.420%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$35.970

高値

$36.500

安値

$34.595

出来高

0.76M

企業ファンダメンタルズ

時価総額

971.8M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.52M

取引所

NMS

通貨

USD

52週レンジ

安値 $12.21現在値 $34.740高値 $38.385

関連ニュース

GlobeNewswire

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.

もっと見る
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president

もっと見る
Anaptys Announces Participation in November Investor Conferences
Analyst Upgrades

Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80

Stifel analyst Alex Thompson maintains AnaptysBio with a Buy and raises the price target from $55 to $80.

もっと見る
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
GlobeNewswire

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including

もっと見る
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation